US › Healthcare

Veru Inc (VERU)

US · Healthcare · Biotechnology

$2.30-5.74%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.0M

EPS

$-0.30

EPS estimate

$-0.32

EPS came in at -0.30 against a street estimate of -0.32 — a beat of 6.3%.

Key statistics

Market cap

$37.6M

Forward P/E

117.6

P/B

1.48

Book value

$1.66

EPS (TTM)

$-0.61

52-week high

$4.54

52-week low

$2.05

50-day MA

$2.54

200-day MA

$2.50

Beta

-1.20

Analyst view

Analysts rate Veru Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $25.67.

Shareholding

Insiders

9.22%

Institutions

19.64%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	4.10%
Alyeska Investment Group, L.P.	1.40%
Oppenheimer & Co Inc	1.24%
BlackRock Inc	0.98%
Renaissance Technologies Corp	0.96%
GSA Capital Partners LLP	0.92%
Geode Capital Management, LLC	0.91%
Summit Financial LLC	0.83%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Veru Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.